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Background: Resistant hypertension is a common clini-
cal problem and greatly increases the risk of target or-
gan damage.
Methods: We evaluated the characteristics of 279 con-
secutive patients with resistant hypertension (uncon-
trolled despite the use of 3 antihypertensive agents) and
53 control subjects (with normotension or hyperten-
sion controlled by using 2 antihypertensive medica-
tions). Participants were prospectively examined for
plasma aldosterone concentration, plasma renin activ-
ity, aldosterone to renin ratio, brain-type natriuretic pep-
tide, atrial natriuretic peptide, and 24-hour urinary al-
dosterone (UAldo), cortisol, sodium, and potassium values
while adhering to a routine diet.
Results: Plasma aldosterone (P .001), aldosterone to
renin ratio (P .001), 24-hour UAldo (P=.02), brain-
type natriuretic peptide (P=.007), and atrial natriuretic
peptide (P=.001) values were higher and plasma renin
activity (P=.02) and serum potassium (P .001) values
were lower in patients with resistant hypertension vs con-
trols. Of patients with resistant hypertension, men had
significantly higher plasma aldosterone (P=.003), aldo-
sterone to renin ratio (P=.02), 24-hour UAldo (P .001),
and urinary cortisol (P .001) values than women. In uni-
variate linear regression analysis, body mass index
(P=.01), serum potassium (P .001), urinary cortisol
(P .001), urinary sodium (P=.02), and urinary potas-
sium (P .001) values were correlated with 24-hour
UAldo levels. Serum potassium (P=.001), urinary po-
tassium (P .001), and urinary sodium (P=.03) levels
were predictors of 24-hour UAldo levels in multivariate
modeling.
Conclusions: Aldosterone levels are higher and there is
evidence of intravascular volume expansion (higher brain-
type and atrial natriuretic peptide levels) in patients with
resistant hypertension vs controls. These differences are
most pronounced in men. A significant correlation be-
tween 24-hour urinary aldosterone levels and cortisol ex-
cretion suggests that a common stimulus, such as corti-
cotropin, may underlie the aldosterone excess in patients
with resistant hypertension.
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R ESISTANT HYPERTENSION ISdefined as blood pressure(BP) that remains higherthan the goal value despitethe use of 3 antihyperten-
sive medications, 1 ideally being a di-
uretic, with all agents prescribed at doses
that provide optimal benefit.1,2 Although
the prevalence of resistant hypertension
is unknown, evidence from the National
Health and Nutrition Examination Sur-
vey and from large randomized clinical
studies3-6 indicates that 20% to 30% of hy-
pertensive persons may require 3 or more
antihypertensive agents to achieve treat-
ment goals. Patients with resistant hyper-
tension are at a disproportionately high risk
for target organ damage and cardiovascu-
lar events.7 Some factors associated with
poor BP control include older age, more
severe hypertension, chronic kidney dis-
ease, female sex, black race, obesity, and
diabetes mellitus.3,4 Although these pa-
tient characteristics are known to be as-
sociated with poorly controlled hyperten-
sion, mechanisms that underlie resistant
hypertension remain poorly elucidated.
Recent studies indicate that primary al-
dosteronism (PA) is a common cause of re-
sistant hypertension. A study8 of 88 con-
secutive patients with resistant hypertension
reported a 20% prevalence of PA (defined
as plasma renin activity1.0 ng/mL/h and
a urinary aldosterone [UAldo] level 12
µg/24 h during high urinary sodium [UNa]
excretion [200 mEq/24 h]). Consistent
with these findings, other medical centers
have reported a prevalence of PA of 17%
to 22% in patients with resistant hyperten-
sion.9-11 The reason for the high preva-
lence of aldosterone excess in patients with
resistant hypertension is unknown.
We hypothesize that aldosterone con-
tributes broadly to antihypertensive drug
treatment resistance. In the present study,
we seek to identify potential stimuli of ex-
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cessive aldosterone secretion in patients with resistant
hypertension.
METHODS
Consecutive patients referred to the University of Alabama at
Birmingham Hypertension Clinic for resistant hypertension were
studied prospectively during a 6-year period (January 1, 2001,
to December 31, 2006). Patients with resistant hypertension
included those with uncontrolled hypertension (140/90
mm Hg) at 2 clinic visits despite the use of 3 antihypertensive
medications at pharmacologically effective doses. We re-
ported a high prevalence of obstructive sleep apnea and a cor-
relation between aldosterone levels and the severity of obstruc-
tive sleep apnea in patients with resistant hypertension.12 Hence,
consecutive patients referred to the University of Alabama at
Birmingham Sleep/Wake Disorders Center for possible obstruc-
tive sleep apnea and without resistant hypertension (with nor-
motension or BP controlled by taking2 antihypertensive medi-
cations) were recruited as control subjects to match the patients
with resistant hypertension for age, sex, race, body mass in-
dex, and the likelihood of obstructive sleep apnea. The study
was approved by the University of Alabama at Birmingham in-
stitutional review board and was conducted according to
institutional guidelines. All the patients provided written in-
formed consent before study enrollment.
All the patients had been adhering to a stable antihyperten-
sive drug regimen for at least 4 weeks before examination. Pa-
tients were examined during continuation of their normal medi-
cation regimens except for spironolactone, amiloride
hydrochloride, and eplerenone, which were discontinued at least
6 weeks before enrollment. Secondary causes of hypertension
other than PA, such as renovascular hypertension, pheochro-
mocytoma, and Cushing syndrome, were excluded by labora-
tory analysis or radiologic imaging as clinically indicated. Pa-
tients with a history of congestive heart failure, chronic kidney
disease (creatinine clearance 60 mL/min/1.73 m2 [to con-
vert to milliliters per second per square meter, multiply by
0.0167]), or long-term corticosteroid therapy were excluded
from study participation.
Seated clinic BP was measured manually using a mercury
sphygmomanometer and an appropriate-sized cuff after 5 min-
utes of rest. A mean of 2 readings was taken. All patients with
resistant hypertension underwent 24-hour ambulatory BP moni-
toring (model 90207 [Spacelabs Healthcare, Issaquah, Wash-
ington] or model 0413 [Suntech Medical, Morrisville, North
Carolina]).
Biochemical evaluation was performed for all the patients
on an outpatient basis. Early morning (7-9 AM) blood samples
were collected from patients in the seated position for serum
chemistry results, plasma aldosterone concentration (PAC)
(reference range, 4-31 ng/dL [to convert to picomoles per
liter, multiply by 27.74]) and plasma renin activity (PRA)
(reference range, 1.31-3.95 ng/mL/h). Twenty-four hour urine
collection for the measurement of UAldo (reference range,
2-16 µg/24 h), UNa, and creatinine was performed while the
patient followed a routine diet. Measurement of plasma meta-
nephrines (reference range, 0-90 pg/mL [to convert to pico-
moles per liter, multiply by 5.459]), normetanephrines (refer-
ence range, 0-163 pg/mL [to convert to picomoles per liter,
multiply by 5.459]), brain-type natriuretic peptide (BNP) (ref-
erence range, 0-100 pg/mL [to convert to nanograms per liter,
multiply by 1.0]), atrial natriuretic peptide (ANP) (reference
range, 0-100 pg/mL [to convert to picomoles per liter, multi-
ply by 0.325]), 24-hour urinary potassium (UK), and 24-hour
urinary cortisol (UCort) (reference range, 56-286 µg/24 h)
was added to the protocol after study initiation. From that
point forward, all the patients with resistant hypertension
(n=135) and all the control subjects underwent this addi-
tional testing. The PAC, PRA, and UAldo levels were mea-
sured at commercial laboratories (Quest Diagnostics, Atlanta,
Georgia, and Mayo Medical Laboratories, Rochester, Minne-
sota) using standard techniques. Blood samples for ANP mea-
surements were collected in EDTA tubes and were centrifuged
after adding the protease inhibitor aprotinin, which stabilizes
ANP. Samples were frozen at −80°C. The ANP level was mea-
sured by means of radioimmunoassay using commercially
available kits (Phoenix Pharmaceuticals Inc, Burlingame, Cali-
fornia). The aldosterone to renin ratio (ARR) was calculated
as PAC divided by PRA. Patients with UAldo excretion of 12
µg/24 h or greater and PRA of 1.0 ng/mL/h or less were con-
sidered to have a high aldosterone status. All other patients
were considered to have a normal aldosterone status.
Values are reported as mean (SEM) for continuous vari-
ables. Differences between groups are compared using the un-
paired t test for continuous variables and the Fisher exact test
for categorical variables (sex and race). Predictors of aldoste-
rone levels were assessed by means of univariate and multiple
regression analysis using a software program (SAS, version 9.1;
SAS Institute Inc, Cary, North Carolina). Because UAldo levels
in this study population were not normally distributed, the natu-
ral log of UAldo was used in the multivariate model to predict
UAldo levels. P .05 was considered statistically significant.
RESULTS
A total of 279 patients with resistant hypertension (135
men and 144 women) and 53 controls (29 men and 24
women) were examined. Overall, 60% of the patients with
resistant hypertension had suppressed PRA (1.0 ng/
mL/h) vs only 40% of controls. Thirty-five percent of the
patients with resistant hypertension had an elevated ARR
(20), and 29% had elevated 24-hour UAldo levels (12
µg/24 h) and suppressed PRA (1.0 ng/mL/h). In con-
trast, only 4% of controls had an elevated ratio with the
use of either plasma or urinary aldosterone levels. Of the
patients with resistant hypertension, 84.9% were taking
thiazide diuretics (3.6% were receiving both a loop and
a thiazide diuretic), 76.3% were taking calcium channel
antagonists, 71.0% were taking -blockers, 57.3% were
taking angiotensin-converting enzyme inhibitors, 51.6%
were taking angiotensin receptor blockers, 10.0% were
taking -antagonists, and 44.4% were taking other an-
tihypertensive medications, including centrally acting
agents or vasodilators.
Patients with resistant hypertension were older and
more likely to be African American than were control sub-
jects (Table1). The clinic systolic and diastolic BP, PAC,
UAldo, ARR, BNP, and ANP values were all higher in pa-
tients with resistant hypertension than in controls (Table 1
and Figure 1A). The ANP and BNP values were incre-
mentally higher in patients with a high aldosterone sta-
tus (UAldo level 12 µg/24 h and PRA 1.0 ng/mL/h)
vs patients with a normal aldosterone status (UAldo level
12 µg/24 h or PRA 1.0 ng/mL/h) vs controls
(Figure 1B). The PRA levels were lower in patients with
resistant hypertension despite widespread use of agents
known to increase PRA, and serum potassium levels were
also lower, perhaps as a consequence of greater diuretic
use or higher aldosterone levels (Table 1).
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Of patients with resistant hypertension, men had sig-
nificantly greater PAC, ARR, UAldo, UCort, UNa, and
UK values compared with women (Table 2). Men had
higher aldosterone levels despite greater dietary sodium
intake, as evident from greater UNa excretion. In women,
aldosterone levels were not related to menopausal sta-
tus (determined based on patient report or surgical meno-
pause) or to the use of menopausal hormone therapy. The
PAC, ARR, UAldo, and UNa values did not differ be-
tween male and female control subjects. The UCort level
was significantly higher in male than in female controls.
This sex difference in aldosterone remained significant
after correcting for serum potassium concentration. How-
ever, no such sex difference was noted when corrected
for UK concentration.
Black patients with resistant hypertension had higher
clinic systolic BP (148 [1.8] vs 144 [1.7] mm Hg; P=.07),
diastolic BP (89 [1.4] vs 83 [1.1] mm Hg; P .001), 24-
hour ambulatory systolic BP (146 [1.8] vs 140 [1.4] mm Hg;
P=.01), and 24-hour ambulatory diastolic BP (86 [1.2] vs
81 [1.1] mm Hg; P .001) compared with white patients.
ThePACwassignificantly lower inblackpatients (11.2 [0.7]
vs 14.6 [0.8] ng/dL; P .001), and no statistically signifi-
cant racial differences were noted in UAldo levels or PRA.
The 24-hour ambulatory systolic/diastolic BP in all the
patients with resistant hypertension was 143 [1.7]/83 [1.4]
mm Hg. Consistent with previous reports from this labo-
ratory,13 multivariate analysis indicated that older age, male
sex, black race, and high aldosterone status were associ-
ated with higher ambulatory BP monitoring levels.
Univariate linear regression analysis showed that in pa-
tients with resistant hypertension, 24-hour UAldo excre-
tion correlated with body mass index (r=0.15, P=.01), se-
rum potassium (r=−0.23, P .001), UCort (r=0.29,
P .001) (Figure 2), UNa (r=0.20, P=.02), and UK
(r=0.55, P .001) values. Multivariate regression model-
ing with age, sex, race, body mass index, serum potas-
sium, UK, UNa, and UCort as covariates indicated that se-
rum potassium (coefficient=−0.325, P=.001) and UNa
(coefficient=−0.001, P=.03) levels were negatively re-
lated and UK (coefficient=0.012, P .001) was positively
related to UAldo level. The R2 was 43.6% for this model.
COMMENT
The present study adds to the body of literature relating
aldosterone excess to the pathogenesis of resistant hy-
pertension by demonstrating that (1) PAC and 24-hour
Table 1. Characteristics of the Study Participants
Characteristic
Patients With
Resistant
Hypertension
(n=279)a
Controls
(n=53)a
Male sex, % 48.3 54.7
Black race, % 47.3b 28.3
Age, y 54 (0.7)b 50 (1.4)
BMI 33.0 (0.4) 33.9 (0.9)
Clinic systolic/diastolic BP,
mm Hg
146 (1.2)c/86 (0.9)c 125 (1.4)/79 (1.0)
No. of BP medications 4.1 (0.07)c 0.5 (0.10)
Potassium, mEq/L 3.9 (0.03)c 4.3 (0.06)
Plasma aldosterone, ng/dL 13.0 (0.5)c 8.4 (0.7)
Plasma renin activity,
ng/mL/h
2.3 (0.2)b 3.8 (0.9)
Plasma ARR 22 (1.7)c 6 (0.7)
Plasma metanephrines,
pg/mL
36.6 (1.8) 36.6 (1.8)
Plasma normetanephrines,
pg/mL
122.7 (5.5) 108.1 (5.5)
Urinary aldosterone, µg/24 h 13.0 (0.6)b 9.7 (0.9)
Urinary cortisol, µg/24 h 91.2 (3.7) 97.4 (5.4)
Urinary sodium, mEq/24 h 187 (5.2) 181 (14.1)
Urinary potassium, mEq/24 h 64 (2.1) 66 (3.1)
BNP, pg/mL 37.2 (3.1)b 22.5 (3.4)
ANP, pg/mL 95.9 (5.8)c 54.8 (4.9)
Abbreviations: ANP, atrial natriuretic peptide; ARR, aldosterone to renin
ratio; BMI, body mass index (calculated as weight in kilograms divided by
height in meters squared); BNP, brain-type natriuretic peptide; BP, blood
pressure.
SI conversion factors: To convert ANP to picomoles per liter, multiply by
0.325; to convert BNP to nanograms per liter, multiply by 1.0; to convert
plasma aldosterone to picomoles per liter, multiply by 27.74; to convert
plasma metanephrines and normetanephrines to picomoles per liter, multiply
by 5.459; and to convert potassium to millimoles per liter, multiply by 1.0.
aData are given as mean (SEM) unless otherwise indicated.
bDifferent from controls, P .05.
cDifferent from controls, P .001.
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Figure 1. Atrial natriuretic peptide (ANP) and brain-type natriuretic peptide
(BNP) values in patients with resistant hypertension (n=279) vs controls
(n=53) (A) and in patients with resistant hypertension with a normal
aldosterone status (n=197) or a high aldosterone status (n=82) vs controls
(n=53) (B). There was a significant incremental increase in ANP and BNP
values among controls, patients with resistant hypertension with a normal
aldosterone status, and patients with resistant hypertension with a high
aldosterone status. To convert ANP to picomoles per liter, multiply by 0.325;
to convert BNP to nanograms per liter, multiply by 1.0. Error bars
represent SEM.
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UAldo excretion are significantly higher in patients with
resistant hypertension vs control subjects; (2) aldoste-
rone levels are higher in men than in women with resis-
tant hypertension; (3) BNP and ANP levels are higher in
patients with resistant hypertension, irrespective of al-
dosterone levels, suggesting that increased intravascu-
lar volume is a common characteristic of resistant hy-
pertension; and (4) 24-hour excretion of UAldo and UCort
is positively correlated in patients with resistant hyper-
tension, suggesting a stimulus common to both as the
underlying cause of the excessive aldosterone secretion.
Although previous studies, including our own, have re-
ported a prevalence of PA of approximately 20% in pa-
tients with resistant hypertension, none specifically com-
pared aldosterone levels in a control group. In the present
study, we make such a comparison and confirm overall
higher levels of plasma and 24-hour urinary aldosterone
in patients with resistant hypertension. In addition, 34.7%
of the patients with resistant hypertension had an el-
evated ARR compared with only 3.7% of control subjects.
These findings suggest a potentially greater role of aldo-
sterone in causing resistance to antihypertensive agents than
only in patients with classically defined PA. Such an effect
is supported by recent studies14-16 documenting the broad
antihypertensive benefit of aldosterone antagonists in treat-
ing resistant hypertension.
The present results demonstrate significantly higher lev-
els of aldosterone in men with resistant hypertension com-
pared with women. This sex difference is the opposite of
findings from studies17,18 of patients with normotension or
mild hypertension in which PACs were higher in female
patients. Accordingly, the present data indicate that pa-
tients with resistant hypertension are distinct from the more
general hypertensive population, with men having higher
aldosterone levels than women of similar age and body
weight. In a post hoc examination of the present female
patients with resistant hypertension, aldosterone levels were
not related to postmenopausal status or to the use of meno-
pausal hormone therapy, suggesting that the sex differ-
ence in aldosterone levels is not likely to be related to the
presence or absence of female sex hormones.
When corrected for UK excretion, the sex differ-
ences in aldosterone levels were no longer significant. This
suggests 2 possibilities: the greater dietary potassium in-
take by men is stimulating increased aldosterone re-
lease or higher aldosterone levels in men are inducing
greater potassium excretion. Intuitively, it seems that if
greater dietary potassium is stimulating the increased al-
dosterone release in men, there would be concomi-
tantly higher serum potassium levels because this should
better reflect the stimulatory effects of potassium at the
level of the adrenal gland. However, just the opposite is
observed, with men having lower serum potassium lev-
els (3.85 [0.04] vs 3.94 [0.04] mEq/L; P=.08) (to con-
vert potassium to millimoles per liter, multiply by 1.0).
This observation seems to argue against potassium in-
take stimulating increased aldosterone release as op-
posed to excess aldosterone promoting increased potas-
sium wasting. However, the observational design of the
present study cannot distinguish between these 2 pos-
sibilities, and interventional studies are needed to deter-
mine which is the predominant effect.
Table 2. Characteristics of Male and Female Patients
With Resistant Hypertension
Characteristic
Men
(n=135)a
Women
(n=144)a
Black race, % 39b 56
Age, y 54 (0.92) 55 (0.93)
BMI 32.6 (0.46) 33.4 (0.68)
Clinic systolic/diastolic BP,
mm Hg
146 (1.8)/88 (1.16)c 145 (1.7)/84 (1.35)
24-h ambulatory systolic/
diastolic BP, mm Hg
144 (1.5)/86 (0.9)b 143 (1.8)/81 (1.4)
No. of BP medications 4.18 (0.10) 4.10 (0.09)
Potassium, mEq/L 3.85 (0.04) 3.94 (0.04)
Plasma aldosterone, ng/dL 14.8 (0.8)b 11.3 (0.7)
Plasma renin activity,
ng/mL/h
2.20 (0.3) 2.35 (0.3)
Plasma ARR 26 (2.8)c 18 (1.9)
Plasma metanephrines,
pg/mL
42.1 (1.8) 44.0 (1.8)
Plasma normetanephrines,
pg/mL
122.7 (9.2) 122.7 (7.3)
Urinary aldosterone, µg/24 h 16.0 (0.9)d 10.2 (0.7)
Urinary cortisol, µg/24 h 107.8 (5.0)d 76.5 (4.9)
Urinary sodium, mEq/24 h 214 (7.7)d 161 (6.1)
Urinary potassium, mEq/24 h 77 (3.2)d 52 (2.0)
BNP, pg/mL 31.5 (4.0) 42.2 (4.6)
ANP, pg/mL 88.9 (7) 103.3 (9.3)
Abbreviations: See Table 1.
SI conversion factors: To convert ANP to picomoles per liter, multiply by
0.325; to convert BNP to nanograms per liter, multiply by 1.0; to convert
plasma aldosterone to picomoles per liter, multiply by 27.74; to convert
plasma metanephrines and normetanephrines to picomoles per liter, multiply
by 5.459; and to convert potassium to millimoles per liter, multiply by 1.0.
aData are given as mean (SEM) unless otherwise indicated.
bDifferent from women, P .005.
cDifferent from women, P .05.
dDifferent from women, P .001.
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Figure 2. Correlation between 24-hour urinary aldosterone (UAldo)
(reference range, 2-16 µg/24 h) and urinary cortisol (UCort) (reference
range, 56-286 µg/24 h) levels in patients with resistant hypertension (A) and
controls (B).
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Similarly, multivariate modeling identified UNa, se-
rum potassium, and UK levels to be the best predictors
of UAldo levels. The inverse relation with UNa is con-
sistent with high dietary sodium intake suppressing al-
dosterone release, whereas the positive relation with UK
and the negative relation with serum potassium are con-
sistent with high dietary potassium intake stimulating al-
dosterone release or aldosterone excess promoting UK
excretion.19,20 Again, separating cause from effect in terms
of aldosterone and potassium may be important in ex-
plaining the high degree of aldosterone excess in pa-
tients with resistant hypertension.
The present study is the first, to our knowledge, to
report significantly higher BNP and ANP levels in pa-
tients with resistant hypertension compared with con-
trols. Atrial natriuretic peptide is mainly produced in the
cardiac atria, and BNP is produced mostly in the cardiac
ventricles in response to volume or pressure over-
load.21-24 These findings of higher BNP and ANP levels
in patients with resistant hypertension despite wide-
spread diuretic use support persistent intravascular vol-
ume expansion as an important cause of resistant hyper-
tension. If elevated secondary to volume expansion, the
overall higher levels of natriuretic peptides in patients
with resistant hypertension suggest that persistent fluid
retention is not limited only to patients with measur-
able evidence of aldosterone excess.
Interpretation of the present results to suggest per-
sistent fluid retention separate from higher arterial BP
as an important cause of the higher natriuretic peptide
levels is consistent with findings from Mayo Clinic in-
vestigators,25 who reported that higher intravascular vol-
umes as indexed by thoracic impedance, predicted a fa-
vorable response to increased diuretic use in individuals
with resistant hypertension. The fact that most patients
(84.9%) in the present study were already receiving long-
term thiazide diuretic therapy suggests that thiazide di-
uretics at conventional doses may not be sufficient to over-
come this persistent volume expansion. The broad benefit
of spironolactone in reducing BP in patients with resis-
tant hypertension indicates that it may represent a more
targeted approach, but whether the antihypertensive ben-
efit of spironolactone in this setting is related to in-
creased diuresis needs to be determined.
The finding of a significant positive correlation be-
tween UAldo and UCort excretion in patients with re-
sistant hypertension but not in controls suggests that in
the former group there is a stimulus common to aldo-
sterone and cortisol. If so, corticotropin would be an ob-
vious suspect because it is known to stimulate the re-
lease of aldosterone and cortisol.19,20 Consistent with the
present findings, a cross-sectional study26 comparing hy-
pertensive with normotensive African American indi-
viduals found that hypertensive patients had higher al-
dosterone, lower renin, and higher salivary cortisol levels.
Additional studies are needed to determine whether cor-
ticotropin levels are higher in patients with resistant hy-
pertension compared with controls or whether the pa-
tients with resistant hypertension may be more sensitive
to the stimulatory effects of corticotropin.
Adipocyte-derived secretagogues and genetic poly-
morphisms that affect aldosterone synthase activity have
been implicated as potentially important mediators of al-
dosterone and cortisol secretion.27-29 Whether such fac-
tors may be contributing to higher aldosterone levels in
patients with resistant hypertension is not known. In vitro
studies30,31 have suggested that sympathetic nervous sys-
tem activation may stimulate aldosterone and cortisol re-
lease. However, in the present study, we found no dif-
ferences in sympathetic activation based on the
measurement of plasma metanephrines and normeta-
nephrines, although, admittedly, such values are an in-
sensitive index of sympathetic activity.
The present study is strengthened by its prospective
design, the inclusion of many patients with resistant hy-
pertension, and the comparison with a control group with-
out resistant hypertension. Additional strengths in-
clude assessment of aldosterone, cortisol, sodium, and
potassium excretion by 24-hour urine collection. This
study is limited in having performed all biochemical evalu-
ations during ongoing antihypertensive drug treatment.
Although aldosterone and renin activity are ideally as-
sessed after the withdrawal of medications, this was not
possible for safety reasons in these high-risk patients. Al-
though-blockers predictably suppress and diuretics, an-
giotensin-converting enzyme inhibitors, and angioten-
sin receptor blockers increase PRA, effects on aldosterone
release are minimal or absent.9
In conclusion, the present study implicates aldoste-
rone excess and persistent intravascular volume expan-
sion as common underlying causes of resistant hyper-
tension. Increased intravascular volume is not limited to
patients with measurable evidence of aldosterone ex-
cess, suggesting that either factors other than aldoste-
rone contribute to fluid retention or conventional as-
sessments of aldosterone levels do not accurately reflect
the functional role of aldosterone in maintaining fluid
excess. In patients with resistant hypertension, hyperal-
dosteronism is more common in men, indicating a sexual
dichotomy that has not been previously described, to our
knowledge. Last, in patients with resistant hyperten-
sion, a significant positive correlation between aldoste-
rone concentration and cortisol excretion suggests a com-
mon but as yet unidentified stimulus as a potential
mediator of the aldosterone excess in these patients.
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